An interventional study of iovera° in Total Knee Arthroplasty, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 22 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-21.
Sponsored by Pacira Pharmaceuticals, Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to investigate whether iovera° treatment prior to TKA decreases cumulative participant opioid use over the course of 6 weeks following TKA while maintaining similar levels of pain relief. The study will also investigate whether there is a relationship between participants treated with iovera° and participant reported pain and function as measured by knee injury and osteoarthritis outcomes score (KOOS JR), numeric rating scale (NRS) for pain; use of hospital services post-TKA and improved physical rehabilitation as measured by range of motion.
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 17 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Iovera° device presurgical cryoneurolysis treatment, 5 (+/- 2) days prior to TKA. Additionally, all participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
Device: iovera°
All participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
Cumulative Opioid Consumption
The cumulative consumption of opioids was determined from the time of Total Knee Arthroplasty (TKA) surgery to 6 weeks post-TKA surgery. Opioid consumption was converted to morphine milligram equivalents (MME) and participant consumption was verified by pill count at follow-up visits. The cumulative morphine equivalent was divided by the number of days to provide the total daily morphine equivalent (TME) for the participant,
Time frame: From the time of TKA surgery to 6 weeks post-TKA surgery
Area Under the Curve (AUC)/Time for Change From Baseline in Knee Injury and Osteoarthritis Outcomes Score (KOOS JR.) Overall Score Through 6 Weeks Post-TKA
The KOOS JR. was a participant completed questionnaire that consists of 7 questions from 3 subscales: stiffness (1 question), pain (4 questions), and function in daily living (2 questions). Standardized answer options are given (5 Likert boxes) and each question was assigned a score from none (0) to extreme (4). A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) was calculated. A positive change from baseline indicates improvement. AUC/time based on Changes from Baseline in KOOS JR. scores through 6 weeks post-TKA, is the AUC of Change in KOOS JR. scores from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the KOOS JR. score at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.
Time frame: Baseline to 6 weeks post-TKA surgery
AUC/Time for Change From Baseline in Numeric Rating Scale (NRS) for Pain Through 6 Weeks Post-TKA
NRS was an 11-point scale for self-reporting of pain intensity by participants. Scores range from 0 to 10, where 0 points equals "no pain" and 10 points equals the "worst pain imaginable". A positive change represented improvement (or reduction) in pain intensity. AUC/time based on Changes from Baseline in NRS Pain score through 6 weeks post-TKA, is the AUC of Change in NRS for Pain score from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the NRS for Pain score at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.
Time frame: Baseline to 6 weeks post-TKA surgery
AUC/Time for Change From Baseline in Timed Get Up and Go (TUG) Tests Through 6 Weeks Post-TKA
The time required by the participants to raise from sitting, walk 10 feet, turn around, walk back and sit back down was measured in seconds. A positive change from baseline indicates improvement. AUC/time based on Changes from Baseline in the TUG test through 6 weeks post-TKA, is the AUC of Change in TUG test from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the TUG test at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.
Time frame: Baseline to 6 weeks post-TKA surgery
| Milestone | Iovera° Device Treatment Group | Standard of Care Treatment Group |
|---|---|---|
| Started | 62 | 62 |
| Safety population: received study treatment | 59 | 60 |
| Completed | 57 | 58 |
| Not completed | 5 | 4 |
| Withdrew: Adverse event (ae)/serious adverse event (sae) | 1 | 2 |
| Withdrew: Investigator decision | 2 | 0 |
| Withdrew: Missed visit 6 (week 6 visit) | 0 | 1 |
| Withdrew: Fungal infection | 1 | 0 |
| Withdrew: Discharged to rehabilitation | 0 | 1 |
| Withdrew: Missing | 1 | 0 |
The cumulative consumption of opioids was determined from the time of Total Knee Arthroplasty (TKA) surgery to 6 weeks post-TKA surgery. Opioid consumption was converted to morphine milligram equivalents (MME) and participant consumption was verified by pill count at follow-up visits. The cumulative morphine equivalent was divided by the number of days to provide the total daily morphine equivalent (TME) for the participant,
| TME | Iovera° Device Treatment Group | Standard of Care Treatment Group |
|---|---|---|
| Cumulative Opioid Consumption | 4.8 ± 0.7 | 6.1 ± 0.7 |
The KOOS JR. was a participant completed questionnaire that consists of 7 questions from 3 subscales: stiffness (1 question), pain (4 questions), and function in daily living (2 questions). Standardized answer options are given (5 Likert boxes) and each question was assigned a score from none (0) to extreme (4). A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) was calculated. A positive change from baseline indicates improvement. AUC/time based on Changes from Baseline in KOOS JR. scores through 6 weeks post-TKA, is the AUC of Change in KOOS JR. scores from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the KOOS JR. score at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.
| score on a scale/days | Iovera° Device Treatment Group | Standard of Care Treatment Group |
|---|---|---|
| Area Under the Curve (AUC)/Time for Change From Baseline in Knee Injury and Osteoarthritis Outcomes Score (KOOS JR.) Overall Score Through 6 Weeks Post-TKA | 10.3 ± 1.6 | 8.4 ± 1.4 |
NRS was an 11-point scale for self-reporting of pain intensity by participants. Scores range from 0 to 10, where 0 points equals "no pain" and 10 points equals the "worst pain imaginable". A positive change represented improvement (or reduction) in pain intensity. AUC/time based on Changes from Baseline in NRS Pain score through 6 weeks post-TKA, is the AUC of Change in NRS for Pain score from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the NRS for Pain score at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.
| score on a scale/days | Iovera° Device Treatment Group | Standard of Care Treatment Group |
|---|---|---|
| Pain in The Past 7 Days | 2.2 ± 2.1 | 1.7 ± 1.9 |
| Pain Right Now | 1.9 ± 2.7 | 1.5 ± 2.3 |
The time required by the participants to raise from sitting, walk 10 feet, turn around, walk back and sit back down was measured in seconds. A positive change from baseline indicates improvement. AUC/time based on Changes from Baseline in the TUG test through 6 weeks post-TKA, is the AUC of Change in TUG test from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the TUG test at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.
| seconds/days | Iovera° Device Treatment Group | Standard of Care Treatment Group |
|---|---|---|
| AUC/Time for Change From Baseline in Timed Get Up and Go (TUG) Tests Through 6 Weeks Post-TKA | -1.2 ± 5.5 | -0.4 ± 11.3 |
Collected over From first treatment up to the end of the study (Up to approximately 12 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iovera° Device Treatment Group | 0/62 (0%) | 2/59 (3.4%) | 4/59 (6.8%) |
| Standard of Care Treatment Group | 0/62 (0%) | 2/60 (3.3%) | 3/60 (5%) |
| Event | Iovera° Device Treatment Group | Standard of Care Treatment Group |
|---|---|---|
| Bilateral Pulmonary EmboliVascular disorders | 1/59 | 0/60 |
| R/O Popliteal Arterial AneurysmVascular disorders | 1/59 | 0/60 |
| Neuropsychotic/seizuresPsychiatric disorders | 1/59 | 1/60 |
| AnaphylaxisSkin and subcutaneous tissue disorders | 1/59 | 1/60 |
| Event | Iovera° Device Treatment Group | Standard of Care Treatment Group |
|---|---|---|
| R/O Deep vein thrombosisVascular disorders | 4/59 | 3/60 |
Intent-to-Treat (ITT) population included all participants who were randomized into the study.
| Age, Continuous(years) | Iovera° Device Treatment Group | Standard of Care Treatment Group | Total |
|---|---|---|---|
| Mean | 65.5 ± 8.2 | 66.2 ± 7.1 | 65.9 ± 7.6 |
| Sex: Female, Male(Participants) | Iovera° Device Treatment Group | Standard of Care Treatment Group | Total |
|---|---|---|---|
| Female | 31 | 36 | 67 |
| Male | 31 | 26 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Iovera° Device Treatment Group | Standard of Care Treatment Group | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 62 | 62 | 124 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Iovera° Device Treatment Group | Standard of Care Treatment Group | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| Black or African American | 10 | 15 | 25 |
| White | 52 | 47 | 99 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Mar 2019, 16 months.
Results were first posted in May 2021, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.